News
THE HILL TIMES | Personalized medicine is the future of health care
It’s small wonder that buying drugs is expensive. The federal government is consulting on whether a national pharmacare program can reduce costs, while providing coverage to vulnerable populations. But there is a complementary avenue to be explored that promises to lower healthcare costs and revitalize Canada’s pharmaceutical industry—personalized medicine.
Op-ed by Philippe Gros, deputy vice-principal, research and innovation, McGill University, and Officer of the Order of Canada and Mark Lathrop, professor of Human Genetics, and director of the McGill and Genome Quebec Innovation Center.